

# Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

## Anti-cdc2, phospho (Thr14) Antibody, Unconjugated

RRID:AB\_823465

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 2543, RRID:AB\_823465

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_823465](http://antibodyregistry.org/AB_823465)

**Proper Citation:** Cell Signaling Technology Cat# 2543, RRID:AB\_823465

**Target Antigen:** cdc2, phospho (Thr14)

**Host Organism:** drosophila

**Clonality:** unknown

**Comments:** Applications: W

**Antibody Name:** Anti-cdc2, phospho (Thr14) Antibody, Unconjugated

**Description:** This unknown targets cdc2, phospho (Thr14)

**Target Organism:** monkey, rat, hamster, simian, xenopus, mouse, drosophila, bovine, human

**Antibody ID:** AB\_823465

**Vendor:** Cell Signaling Technology

**Catalog Number:** 2543

**Record Creation Time:** 20250819T234126+0000

**Record Last Update:** 20250820T060702+0000

---

### Ratings and Alerts

No rating or validation information has been found for Anti-cdc2, phospho (Thr14) Antibody, Unconjugated.

No alerts have been found for Anti-cdc2, phospho (Thr14) Antibody, Unconjugated.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Joo YK, et al. (2025) The mitotic ATR-Chk1 pathway promotes CDK1 activity for faithful chromosome segregation. Cell reports, 44(8), 116019.

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics, 23(10), 1494.

Serpico AF, et al. (2022) Compartmentalized control of Cdk1 drives mitotic spindle assembly. Cell reports, 38(4), 110305.